7-day roundup
The 10 most notable cure or vaccine studies from the last week.
A trial tests different conditioning regimens before stem cell transplants in children with acute lymphoblastic leukemia to improve survival.
Read lead report →A trial tests CTX112, an engineered T-cell therapy, for severe neurologic autoimmune diseases like progressive MS and stiff-person syndrome.
Read report →An early trial tests a gene therapy for homozygous familial hypercholesterolemia, aiming to lower LDL cholesterol by restoring LDL receptor function.
Read report →A gene therapy trial tests whether modified stem cells can treat metachromatic leukodystrophy, a rare genetic disease.
Read report →A phase 1 trial tests IL-18 armored STEAP1 CAR T cells in metastatic castration-resistant prostate cancer, aiming to see if they are safe and effective.
Read report →A phase 1 trial tests VV169, an in-body CAR-T therapy, for relapsed or refractory multiple myeloma. Learn about safety and early efficacy.
Read report →A phase I/IIa trial tests CD19 CAR-T cell therapy (TranspoCART19) for safety and remission in refractory lupus nephritis.
Read report →A phase 3 trial tests an mRNA flu vaccine against a licensed one in adults 65+ to see if it prevents flu illness better.
Read report →Researchers test LBVD, a liquid hexavalent vaccine, in infants to see if it protects against six diseases as well as current vaccines.
Read report →A phase 1 trial tests a higher dose of the VIR-1388 HIV vaccine in adults with CMV, aiming to trigger immune responses against HIV.
Read report →Trials whose completion date fell in this window and whose status is actually Completed. Results usually follow later.